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ABSTRACT 
TOBI KU: Investigating veterinary management choices for canine heartworm disease 
(Dirofilaria immitis) in northern Mississippi 
(Under the direction of Dr. Clarke Atkins) 
 
Canine heartworm disease affects nearly 45% of dogs in endemic regions of the United 
States (Atkins, 2005). There are concerns that the chronic use of macrocyclic lactone 
(ML) preventives to kill adult heartworms (“soft-” or “slow-kill”) may have contributed 
to the development of ML resistance. My study of this problem had three objectives: (a) 
to determine the frequency of “slow-kill” treatment in heartworm-positive patients and 
compare them to practitioner estimates; (b) to survey practitioner opinions on the factors 
influencing heartworm disease management; and (c) to analyze the heartworm prevention 
history of heartworm-positive patients in order to understand the causes of heartworm 
infection in this region. The study group consisted of dogs determined to be heartworm-
positive when presented to a mixed-animal practice in northern Mississippi. Client 
records were scrutinized for heartworm preventive purchase history. Veterinarians in the 
four-doctor practice completed a questionnaire concerning their beliefs and practices in 
regard to heartworm treatment. 75% of heartworm-positive patients received “slow-kill” 
treatment, more than 20% greater than that estimated by the practitioners. 12.5% of 
patients received adulticidal treatment, equivalent to those that received no treatment. 
Injectable moxidectin was the most common ML preventive used in “slow-kill” 
treatment. Client financial concerns were cited as the primary reason for choosing “slow-
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kill” treatment. The results of this study show that practitioner estimates of “slow-kill” 
prevalence within their clinics may be suspect in their accuracy. Despite the 
recommendations of the American Heartworm Society, clients and veterinarians prefer 
the “slow-kill” method of heartworm treatment. However, trends in patient heartworm 
preventive history show that poor client compliance remains the predominant reason for 
heartworm infection. Thus, consistent use of existing, effective heartworm preventives 
should be the primary goal in reducing prevalence of heartworm infection, regardless of 
the recognized threat of resistance. Further study is needed on the risks and efficacy of 
“slow-kill” treatment and the effects of different ML preventives for the treatment of 
heartworm infection. 
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CHAPTER 1 
INTRODUCTION 
Canine heartworm disease significantly impacts the United States, infecting nearly 
45% of dogs in endemic regions (Atkins, 2005). Mosquitos transmit the third larval stage 
from heartworm-infected canines to other canine hosts. Current macrocyclic lactone 
heartworm preventive treatments are extremely effective at stopping canine heartworm 
infection by killing these larval stages. These preventives demonstrated perfect efficacy 
when initially approved by the Food and Drug Administration (Bowman, 2012). 
However, numerous lack-of-efficacy claims filed against some heartworm preventives in 
the last decade combined with the isolation of preventive-resistant heartworm strains 
have sparked increasing concern regarding the development of heartworm resistance to 
macrocyclic lactones (Bowman, 2012). These concerns are especially relevant in the 
southeast United States, which has the nation’s highest incidences of heartworm infection 
(Wang et al., 2014; Bowman et al., 2009) (Figure 1). In order to effectively combat 
canine heartworm disease, it is critical to investigate and understand how it is managed 
by veterinary practitioners and clients in this region. 
While a small body of research on heartworm management in the Mississippi (MS) 
delta region exists, many of these studies rely on retroactive self-report of clinical data 
(Colby et al., 2014; Pulaski et al., 2016). Self-reporting can be unreliable due to 
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individual bias and imperfect recordkeeping. In this study, I analyzed the management of 
canine heartworm disease in a northern MS private practice. 
 
 
 
 
 
 
Figure 1. Geographical prevalence of canine heartworm disease in the United States. 
Source: Companion Animal Parasite Council Parasite Prevalence Maps. Data provided 
by IDEXX Laboratories and ANTECH Diagnostics. Copyright ©CAPC 2017, used with 
permission.  
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Theoretical Framework 
Heartworm disease (HWD) is the pathology caused by prolonged heartworm 
infection (HWI). The parasitic roundworm Dirofilaria immitis resides in the pulmonary 
artery and may cause vascular and respiratory damage to the canine host (Atkins, 2005). 
D. immitis has a multi-stage life cycle: the microfilarial larval stage (L1) is ingested from 
an infected canine host by a feeding female mosquito. After several molts inside the 
mosquito host, the infective third-stage larvae (L3) can be transmitted to new canine 
hosts through additional mosquito feeding events (Atkins, 2005). A summary of the life 
cycle of D. immitis is shown in Figure 2.  
 
 
Figure 2. Life cycle of Dirofilaria immitis. 
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Macrocyclic lactone (ML) preventive therapy, currently the most prevalent method of 
HWD prophylaxis, prevents onset of HWD by killing both the deposited L3 and the next, 
fourth-stage larvae (L4) (Bowman, 2012). Prior to the development of ML preventives in 
the 1980s, daily administration of oral diethylcarbamazine was the only method of D. 
immitis prophylaxis (Kume et al., 1962). Diethylcarbamazine products fail to prevent 
HWI if a single day of administration is skipped, and can also cause death in dogs with 
preexisting HWI due to the cardiovascular blockage resulting from sudden microfilarial 
death (Kurokawa et al., 1963). In contrast, ML preventives are currently recommended 
by the AHS (2014) because of their safety, long-lasting efficacy, and ease of 
administration.  
The two ML subgroups are the avermectins (including ivermectin and selamectin) 
and the milbemycins (moxidectin and milbemycin oxime). They are structurally similar 
to the antibacterial macrolides (McKellar & Benchaoui, 1996). While their modes of 
action have not been fully characterized, MLs primarily act on the glutamate-gated 
chloride channels of filarial excretory and secretory pores, compromising parasite ability 
to avoid host immune defenses (Moreno et al., 2010; AHS, 2014; Mani et al., 2016). ML 
preventives can be administered orally, topically, or subcutaneously and are available in 
many different formulations (Figure 3). These formulations may contain the ML alone or 
include flea, tick, and other endoparasite preventive chemicals. Cost comparisons 
between different HWP methods are difficult to determine accurately as prices are 
influenced by many factors, including veterinary practice pricing mark-ups, method of 
administration, broad-spectrum or heartworm-only preventives, and trade-name or 
generic formulations. Analyses of online distributors can provide a ballpark estimate for 
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the costs of heartworm prevention. For a six-month supply of heartworm prevention 
suitable for a 40-lbs dog, oral heartworm-only preventives such as milbemycin oxime 
(Interceptor®, Elanco Animal Health, Greenfield, IN) typically cost around $40.00, while 
oral combination preventives containing milbemycin oxime and the flea preventive 
spinosad (Trifexis®, Elanco Animal Health) cost around $110.00 (PetMed Express, 
2017). According to the manufacturer, the injectable heartworm-only preventive 
containing moxidectin costs $45.96 on average for a six-month dose (Lavan & Login, 
2015).  
 
Figure 3. Administration of macrocyclic lactone heartworm preventive products. 
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Resistance to macrocyclic lactones. Although ML preventives met perfect standards 
of efficacy when they were first introduced, there is increasing evidence that D. immitis 
may be developing resistance to these compounds. The Food and Drug Administration 
(FDA) Center for Veterinary Medicine saw a dramatic increase in lack-of-efficacy (LOE) 
claims in the beginning of the 21st century, especially in HW-endemic areas of the 
southeast United States (Hampshire, 2005). Clinical practices typically file LOE claims 
to pharmaceutical companies that offer compensation for cases of HW infection in which 
documentation of consistent HW prevention has been maintained, usually in the form of 
client purchase history, and the FDA Center for Veterinary Medicine further compiles 
and analyzes these LOE submissions. Additionally, a 2014 survey found that 74% of all 
Louisiana veterinary practices had seen at least one LOE case within the last year 
(Pulaski et al., 2014), and preliminary results from currently unpublished, ongoing 
questionnaires throughout the MS delta region (Mississippi, Missouri, Alabama, 
Arkansas, and Louisiana) seem to follow this trend (Pulaski et al., 2016). Other 
researchers have discovered and isolated D. immitis microfilaria (L1) that persist through 
ML treatment; for example, during the development of new ML preventive combinations, 
it was found that previously effective compounds were no longer demonstrating perfect 
efficacy with certain D. immitis strains (Bowman, 2012). In recent years, multiple 
research teams have successfully isolated ML-resistant D. immitis strains from LOE cases 
(Bowman, 2012; Pulaski et al., 2014). Thus, it is well accepted that some heartworm 
isolates are resistant to the effects of ML preventives. 
Despite these findings, the impact of D. immitis resistance is poorly understood, in 
part due to the complex nature of the parasite’s life cycle. In suspect resistant D. immitis 
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isolates, certain larval stages are more susceptible to the effects of ML preventives than 
others, such as microfilaria (L1) (Bowman, 2012). Certain therapeutic practices, such as 
the use of ML as a “slow-kill” adulticide in treating heartworm infection (HWI), have 
been suggested as contributing to resistance because they can target highly susceptible 
larval stages while allowing more resistant stages to multiply (Bowman, 2012). In other 
words, such practices may allow for selection of resistance in D. immitis. Additionally, 
although ML resistance is often the suspected cause of ML treatment failures in practice, 
most LOE cases are likely caused by poor compliance to HW preventives leading to 
inconsistent protection coverage (Boman, 2012; Atkins et al., 2014).  
 
American Heartworm Society recommendations for heartworm infection 
treatment. The American Heartworm Society (AHS), an international organization 
founded in 1974, maintains guidelines for the prevention, diagnosis and treatment of 
HWD. The AHS hosts the triennial American Heartworm Symposium, and in 2013 the 
symposium addressed the increasing prevalence of LOEs and ML-resistant isolates. 
These discussions informed the development of the AHS’s Current Guidelines for the 
Prevention, Diagnosis, and Management of Heartworm (Dirofilaria immitis) Infection in 
Dogs (2014). According to these guidelines, the AHS recognizes melarsomine 
dihydrochloride (Immiticide®, Merial Limited, Duluth, GA) as the only FDA-approved 
adulticidal therapy for HWI. Melarsomine dihydrochloride is an arsenical molecule that 
causes death in heartworms that are over four months old, and it is effective for the 
treatment of canine heartworm infection (McTier et al., 1994). The AHS also 
recommends the use of doxycycline in combination with melarsomine adulticidal 
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protocols. Doxycycline targets Wolbachia, endo-symbiotic bacteria that reside in 
Dirofilaria immitis at all life stages and have been implicated in HWD pathogenesis, as 
Wolbachia surface protein has been shown to induce host antibody and inflammatory 
responses (Kramer et al., 2005). Thus, doxycycline therapy has been shown to reduce the 
chance of adverse complications and mortality over the course of HW treatment (AHS, 
2014).  
“Slow-kill” therapy. While regular ML preventive administration is included in the 
AHS’s recommended HW treatment protocol, the continuous use of ML preventives in a 
HW-positive canine without melarsomine with the intent of adulticidal action is known as 
“slow-kill” therapy (AHS, 2014). This is considered an off-label use of ML preventive 
products because they are not approved by the FDA for treating HWI; the mechanism of 
action for “slow-kill” therapy is yet to be understood. “Slow-kill” therapy first became 
prevalent in 2010, when melarsomine began to fall into short supply due to manufacturer 
delays (Becker, 2011); according to the FDA, the melarsomine shortage is still 
unresolved (U.S. Food and Drug Administration, 2016). While studies have demonstrated 
the adulticidal effect of several ML preventives especially in combination with 
doxycycline (McCall et al., 1996; Venco et al., 2004; Bazzocchi et al., 2008; 
Chandrashekar, 2014), the AHS (2014) asserts that the delayed adulticidal effects of these 
products allow unsafe HWD pathology to continue to progress as the worms die slowly. 
Additionally, as previously discussed, there is a possibility that the use of ML preventives 
in “slow-kill” therapy exacerbates the evolution of HW resistance to ML (Bowman, 
2012). For these and other reasons, the AHS (2014) does not recommend the use of 
“slow-kill” therapy in the management of HWD. 
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Comparing treatment options. Treatment of HWI with melarsomine 
dihydrochloride, in this article referred to as adulticidal therapy, differs from “slow-kill” 
treatment in many respects. As stated in the previous section, “slow-kill” therapy usually 
incorporates the administration of heartworm preventive, ideally in combination with 
doxycycline therapy. The AHS (2014) management protocol for HWI recommends that 
adulticidal therapy include administration of heartworm preventive to reduce 
microfilarial counts; prescription of doxycycline to kill endosymbiotic Wolbachia, thus 
reducing inflammatory pathology; ideally, three injections of melarsomine; and exercise 
restriction from the day of diagnosis to six to eight weeks following the last melarsomine 
injection. In other words, the AHS-recommended protocol for adulticidal therapy 
includes those protocols of “slow-kill” therapy with other additional procedures. 
It follows that adulticidal therapy must have greater financial costs than “slow-kill” 
therapy. This comparison is noted in many studies surrounding HWD management 
(Colby et al., 2011; Polak & Smith-Blackmore, 2014), although objective comparisons of 
the average costs of HW treatment have not been performed. Additional financial costs 
may incur if diagnostic methods, such as the blood analyses and radiographs 
recommended by the AHS (2014), are required for understanding and treating the 
patient’s pathology. Non-monetary costs on pet owners should also be considered. 
Confining or restricting the pet’s activity for at least three months over the course of 
adulticidal treatment may be considered inconvenient by many pet owners. Additionally, 
adulticidal administration and diagnostic testing requires prolonged separation between 
pet and owner, including overnight hospitalization. Such separation can understandably 
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cause stress to both pets and their owners alike. A summary of HW treatment 
comparisons is provided in Table 1. 
 
 
 Adulticidal Treatment “Slow-Kill” Treatment 
Therapeutic 
Agents 
Melarsomine Dihydrochloride 
(Immiticide®) + Doxycycline 
 
Macrocyclic Lactone product + 
Doxycycline 
Safety & 
Efficacy 
Only treatment recommended by 
the AHS due to empirical 
evidence for safety and efficacy 
 
Not recommended by the AHS or 
FDA-approved for this purpose; 
may contribute to ML resistance 
Non-monetary 
Considerations 
Inconvenient: requires 
hospitalization, confinement, 
activity restriction; possible 
further clinical workup (e.g. 
bloodwork, radiographs) 
 
Convenient: simple procedure 
with no restrictions necessary; 
clients may return to normal 
routine immediately following 
diagnosis 
Monetary 
Considerations 
Expensive: $1,200-$1,800 + 
preventive cost 
 
Affordable: $50 + preventive 
cost 
 
Table 1. Comparing heartworm treatment options. Monetary data for adulticidal 
treatment is estimated for a 40-lbs dog, provided by the AHS (2013). Monetary data for 
“slow-kill” treatment includes doxycycline cost, obtained from current estimates for 30 
days of doxycycline for a 40-lbs dog in the practice included in this study. 
 
 
 
 
Understanding clinical decision-making. Perhaps due to these factors, the “slow-
kill” method remains a common practice despite AHS recommendations. However, few 
studies have explored its prevalence. A survey of animal shelters in HW-endemic states 
(Florida, Georgia, Alabama, and Mississippi) showed that 22% of the shelters 
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predominantly used “long-term low-dose ivermectin”, or “slow-kill” therapy, as HW 
treatment (Colby et al., 2011). In clinical practice, less than 10% of HW-positive cases in 
veterinary practices surveyed throughout the MS Delta region received “slow-kill” 
therapy, according to preliminary results from an ongoing study (Pulaski et al., 2016).  
The aforementioned study emphasized the need to bridge academic and clinical 
environments in HW treatment, but also mentioned the possible effects of clinician 
opinions and biases on questionnaire analysis results (Pulaski et al., 2016). Indeed, while 
these retrospective analyses of medical records are important tools in observing owner 
compliance and patient histories, there are limitations in performing retrospective 
analyses of veterinarian and pet owner behavior. In a separate, unpublished study (Ku et 
al., 2016), I investigated the role that LOE case frequency may play in ML-resistance 
development in the MS delta through the retroactive analysis of client and medical 
records from a private practice in northern MS. Our study shows that data are difficult to 
obtain from practitioner self-report, and there is also a noticeable dichotomy between 
practitioner perspectives and recorded data.  
In fact, most practices lack the time, appropriate software, or interest to consistently 
and accurately record the clinical justifications for each treatment decision. As a result, 
studies often rely on practitioner self-reporting by memory, and thereby have the 
potential to contain error or personal bias. In one study, even when owners and 
veterinarians believed that a patient had received HW preventive with “perfect” 
compliance, gaps of coverage were still detected in a high number of cases (Atkins et al., 
2014). Accordingly, it is possible that the actual prevalence of “slow-kill” therapy could 
be much greater than that which is self-reported.  
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Research Objectives 
 The purpose of this study is to better understand current treatment decisions 
employed for HW-positive patients, protocols utilized in a “slow-kill” methodology, and 
trends in HW prevention in a region with concerns about ML resistance. The objectives, 
hypotheses, and predictions of this study are summarized in Table 2. 
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 Objective Hypothesis Prediction 
1 To determine the 
frequency of treatment 
types used for HW-
positive canine patients 
and compare them to 
practitioner estimates 
Practitioners typically 
under-report the 
frequency of “slow-kill” 
therapy used in their 
practices. 
Practitioner estimates for 
the percentage of HW-
positive cases treated 
with “slow-kill” therapy 
will be less than the 
actual percentage 
revealed by patient 
medical records in this 
practice. 
2 To survey practitioner 
opinion on the factors 
influencing HWD 
management choices 
Financial concerns are a 
primary factor 
influencing client and 
veterinary treatment 
decisions for patients in 
this region. 
Veterinarians will report 
that clients prefer to use 
the “slow-kill” method of 
HWD treatment due to 
financial concerns. 
3 Analyze HWP history for 
HW-positive patients in 
this practice in order to 
understand the causes of 
HW infection in this 
region 
Lack of compliance to 
existing HWP is the 
primary cause of HWI in 
this region. 
Most HW-positive 
patients will demonstrate 
poor histories of HWP. 
 
Table 2. Research objectives, hypotheses, and predictions. 
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CHAPTER 2 
METHODS 
Participants 
The study was performed at a mixed-animal private practice in Oxford, 
Mississippi, that employs four veterinarians. Oxford falls within the region of high 
density for lack-of-efficacy claims (Hampshire, 2005). From April to June 2016, canine 
patients were tested for HWI using the SNAP HW RT or 4Dx Plus antigen tests (IDEXX 
Laboratories, Westbrook, ME, USA) during routine annual examinations or when 
experiencing appropriate clinical signs, at a doctor’s discretion. This test method was 
chosen primarily because it was the existing HW diagnostic test utilized at the 
participating practice. The SNAP HW RT test has also been shown to be significantly 
more sensitive than other commercial heartworm antigen test kits of its type (Atkins, 
2003). The SNAP test, like all HW antigen tests, can indicate HWI as early as six months 
after transmission. Dogs testing positive for HWI were recorded for further analysis of 
their medical records. 
 
Data Collection 
For HW-positive cases, client transaction records and patient charts were 
scrutinized for HW preventive purchase gaps, purchases for multiple patients in the same 
household, and patient HW testing and/or treatment history. Prevention purchases for 
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multiple patients in the same household were included in the criteria because product 
sharing may indicate possible compromises in HW protection (Atkins et al., 2014). When 
available, heartworm preventive history was studied from two years before positive 
testing, or from birth if the patient was less than two years old. Patients were assigned a 
status under the following criteria (summarized in Table 3): 
a. Consistent –no gaps in coverage greater than three months; such gaps in coverage 
may be realistically accounted for by the retroactive efficacy (“reach-back”) of 
some preventive products (McCall, 2005) 
b. Inconsistent –gaps in coverage greater than three months 
c. None –no record of preventive use 
d. Unknown – patients without available medical records over the period of interest 
(i.e. newly adopted pets) 
The treatment protocols chosen for these heartworm-positive dogs were recorded 
in one of three categories: adulticidal therapy, indicating the administration of 
melarsomine (Immiticide®, Merial Limited, Duluth, GA); “slow-kill” method, indicating 
the off-label use of an ML preventive as an adulticide for active HW infection in addition 
to at least one month of doxycycline; and no treatment. The type of ML preventive used 
for “slow-kill” therapy cases was also recorded in each case.  
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For heartworm (HW)-positive 
patient… 
YES NO 
1 Does client purchase history exist 
for this patient? 
 
Continue to #2 UNKNOWN 
2 Has client purchased HW 
prevention in the two years prior to 
(+) HW test? 
 
Continue to #3 NONE 
3 In this period, is there a gap in HW 
prevention greater than three 
months? 
 
INCONSISTENT CONSISTENT 
 
Table 3. Heartworm prevention history decision tree. 
 
 
 
Practitioner and Client Opinions 
Veterinarians were asked to complete a questionnaire regarding their methods of 
and beliefs with respect to HW treatment protocols. They were asked to estimate the 
percentage of HW-positive dogs diagnosed in this practice that they believed received 
“slow-kill” therapy and whether they began discussions with clients regarding HW 
treatment by introducing adulticidal therapy or “slow-kill” therapy. They were also asked 
to indicate and rank the primary factors that they believe influence clients to choose 
“slow-kill” over adulticidal methods of HW treatment, and to expand on these reasons if 
possible.  
 
Data Sorting and Analysis 
This practice utilized both digital and physical (paper) medical records, so all 
records were pulled from AVImark® software (Logistic, 2009) or physical patient files 
and recorded using Microsoft® Excel (Microsoft Office, 2016). Window-of-Infection 
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(WOI) analyses were performed for patients with a consistent history of HW preventive 
use in the previous two years using the Merial© Window-of-Infection program 
(www.heartwormedu.com). The window of infection is defined as the period of time in 
which the current infection is most likely to have occurred. This time period starts at nine 
months prior to the last negative HW test and ends six months before the positive HW 
test. Purchase gaps of 45 days or more within the WOI indicate compliance failure, and 
argue against product failure (Atkins et al., 2014). 
 
18 
 
 
 
CHAPTER 3 
RESULTS 
Heartworm Prevention Histories 
Of 321 dogs tested for HW over the period of this study, a total of 40 dogs tested 
HW-positive (12.46%). Client records revealed that over half of all HW-positive patients 
had inconsistent (32.5%, n=13) or no history (30.0%, n=12) of HW prevention in the past 
two years (Figure 4). The remaining cases consisted largely of patients with an unknown 
HW prevention history (27.5%, n=11). Few patients had consistent HW preventive 
coverage (10.0%, n=4); one such patient had previously tested positive and was currently 
under “slow-kill” treatment. Window-of-infection (WOI) analyses were performed for 
the remaining three patients that appeared to have a consistent preventive history. These 
analyses identified preventive purchase gaps of >45 days within the WOI for all three of 
the HW-positive patients considered (Figure 5). It is of interest that all three dogs showed 
good compliance after the first purchase of medication, but were infected prior to having 
received heartworm prophylaxis. There were two LOE claims submitted to 
pharmaceutical companies for compensation during this period; both claims were 
submitted from the patients who were considered to have Consistent HW preventive 
coverage.  
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Figure 4. Prevention history for heartworm-positive patients. The shaded region (a) 
in the first column denotes the proportion of cases that were determined to have 
consistent HW prevention coverage were not found to have purchase gaps >45 days after 
WOI analysis (2.5%).   
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Figure 5. Window-of-infection analyses for three heartworm-positive patients. In 
these diagrams, a white circle represents a single heartworm preventive dose, an asterisk 
indicates the purchase of additional preventive medication, and a positive or negative 
symbol denotes the time and result of heartworm testing for the patient in question. These 
dogs (a, b, c) appeared to have consistent heartworm prevention coverage during initial 
scrutiny of patient records, but gaps >45 days were apparent in the WOI analyses. These 
gaps are symbolized by red coloration of the horizontal timeline.  
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Heartworm Treatment Methods 
Results for each heartworm treatment method are summarized in Table 4 and 
Figure 6. Of the HW-positive patients in this study, a majority received treatment using a 
“slow-kill” method (75.0%, n=30). Patients were equally likely to receive an arsenical 
(melarsomine) as no treatment (12.50%, n=5). Of the five patients who received no 
treatment, two were experiencing severe health complications and were euthanized 
before HW treatment could be considered. Another was in the care of a rescue group and 
was transferred to a different organization before HW treatment was considered. The 
remaining two patients received no HW treatment due to client decisions. 
Four different HW preventive choices were utilized for “slow-kill” treatment in 
this practice: injectable moxidectin (ProHeart® 6, Pfizer Inc., Madison, NJ), topical 
moxidectin/imidacloprid (Advantage Multi®, Bayer Animal Health, Shawnee, KS), oral 
milbemycin oxime/spinosad (Trifexis®, Elanco Animal Health), and oral 
ivermectin/pyrantel (Heartgard® Plus, Merial Inc., Duluth, GA) (See Figure 3). Of these 
products, a majority (83.33%, n=25) of cases were treated with injectable moxidectin. 
Oral ivermectin (6.67%, n=2), milbemycin oxime (6.67%, n=2), and topical moxidectin 
(3.33%, n=1) were chosen far less in “slow-kill”. Doxycycline therapy was prescribed for 
85% (n=25) of patients treated with “slow-kill”; for the remaining patients, clients 
declined doxycycline therapy. 
Month Total HW+ Immiticide Slow Kill No Treatment 
April 8 0 7 1 
May 15 4 10 1 
June 17 1 13 3 
Total 40 5 30 5 
 
Table 4. Sample sizes for each heartworm treatment. 
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Figure 6. Heartworm treatment decisions and macrocyclic lactone preventives 
chosen for “slow-kill” treatment. 
 
 
Treatment Methods Questionnaire 
Practitioner questionnaire results are depicted in Figure 7. When asked to estimate 
the treatment decisions regarding their HW-positive canine patients, these veterinarians 
believed on average that 53.75% of HW-positive dogs in this practice received “slow-
kill” therapy (instead of adulticidal treatment or no treatment), although estimates ranged 
from 10.00% to 75.00%, depending on the practitioner (Figure 7a). Each of the 
practitioners reported that when discussing HW treatment options with clients, they 
introduced adulticidal therapy before “slow-kill” therapy options (Figure 7b). 
Factors influencing “slow-kill” therapy choice are shown in Figure 7c. The 
practitioners cited client financial concerns as the primary deciding factor for clients who 
chose “slow-kill” therapy (78.3%) since adulticidal therapy requires additional charges 
for the drug, drug administration and hospitalization. The second-most commonly cited 
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factor was convenience (14.0%) as many clients disliked the confinement aspect of 
adulticidal therapy, particularly in cases involving active, asymptomatic patients. Patient 
age was another influential factor in HW treatment considerations, as clients often 
objected against stressful or expensive treatment procedures for older canines. Arsenical 
concern (2.33%) and preexisting life-threatening disease (2.33%) were less common 
reasons that clients chose “slow-kill” therapy. 
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Figure 7a-c. Practitioner questionnaire and results. (a)The mean practitioner estimate 
is compared with the actual percentage of HW-positive cases treated with “slow-kill” 
therapy in this practice during the study period. The red dots represent the values of 
individual estimates (10.0%, 60.0%, 70.0%, 75.0%). Practitioners underestimated the 
prevalence of “slow-kill” therapy in this study. 
 
 
 
(a)	Estimate	the	percentage	of	dogs	
diagnosed	with	HWI	that	receive	
slow/soft-kill	therapy	in	this	
practice	under	your	care.	
	
A	comparison	between	the	average	
practitioner	estimate	and	the	actual	
value	obtained	in	study	is	depicted.		
	
	
	
		
	
(b)	When	discussing	protocols	for	
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CHAPTER 4 
DISCUSSION 
Causes of Heartworm Infection 
Heartworm infection in this practice resulted most often from inadequate (32.5%), 
unknown (27.5%), or absent (30.0%) ML preventive use. Even in the 10% of HW-
positive dogs that consistently received ML, deeper analysis revealed purchase gaps of 45 
days or greater in three of four cases. Thus, 97.5% of HW-positive patients in this study 
had inadequate HW protection. In a study of HW-positive cases suspected to be a result 
of ineffective HWP, 80.7% of patients were found to have inadequate HWP coverage 
(Atkins et al., 2014). Since the Atkins et al. (2014) study contained a more specific study 
group in which consistent HWP was expected, it is not surprising that they would have a 
lower percentage of HWP incompliance than that of our study. Thus, our results do not 
depart from existing research on HW-positive samples. 
 Furthermore, LOE claims were submitted for only two (0.62%) of the 321 dogs 
tested during this time period. This is consistent with previous observations from an 
epidemiological study exploring the factors that may have contributed to an increase in 
LOE, showing that, over the past 10 years, annual LOE cases made up ≤1.3% of total 
HW tests performed (Ku et al., 2016). An existing survey of the MS delta reports that 
while a large number of practices (26%, n=57) have only seen one to two cases of well-
documented HWP failure in the last year, some practices (16%, n=35) also report having 
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seen 10-50 cases of HWP failure in the past year (Pulaski et al., 2014). Thus, there is a 
wide range of possible LOE caseloads in the MS delta region, and the data from our 
study is consistent with this range. 
Do these LOE cases indicate the possibility of HW resistance in this practice? As 
previously stated, gaps in HW protection were still detected in the two cases submitted 
for LOE consideration. LOE claims may be incorrectly assumed to indicate suspected 
product failure or HW resistance to ML products, especially since increased LOE cases in 
the past decade have raised concerns of HW resistance (Bowman, 2012). However, LOE 
cases may be submitted in any circumstance where patients test HW-positive while 
receiving HWP. Pharmaceutical companies may compensate practitioners or clients in 
cases of alleged product failure, providing an incentive for practitioners to submit LOE 
claims regardless of known gaps in HW protection. Even in cases of inadequate HWP, 
pharmaceutical companies may still provide compensation because some HW 
preventives are advertised to have retroactive or “reach-back” effects that may prevent 
HWI even in the case of missed doses (McCall, 2005). Pharmaceutical companies and the 
FDA Center for Veterinary Medicine have adopted several scoring systems for LOE 
claims that evaluate the possibility of drug ineffectiveness, but reports of LOE frequency 
often neglect the distribution of such scores, resulting in misleading numbers 
(Hampshire, 2005). Thus it is invalid to assume that LOE claims equate to cases of 
resistance since HW protection is often found to be inadequate for the patients under 
consideration (Atkins, 2014).  
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Practitioner Perceptions and Heartworm Management Practices  
In this practice, the majority of HW-positive cases were treated with “slow-kill” 
therapy during the months of this study. These data contrast preliminary results of 
questionnaires in the MS delta region, where practitioners reported “slow-kill” therapy 
usage in less than 10% of HW-positive cases (Pulaski et al., 2016). The in-clinic survey 
results (Figure 4a) from this study show that although these practitioners have higher 
estimates than other veterinarians in the MS delta region, they still underestimate the use 
of “slow-kill” therapy in their own practice (with a percent error of 28.3% between 
estimate average and actual value). These results offer support for our first hypothesis, 
that practitioners typically under-report the frequency of “slow-kill” therapy used in their 
practices. 
There is a large disparity between the estimates made by different practitioners in 
the clinic, with the greatest outlier being one practitioner’s very low estimate of only 10% 
of cases being treated with “slow-kill”. Possible explanations for this disparity include 
differences in individual HW treatment decisions, variable exposure to HWD 
management due to the division of practitioner duties within the clinic, and personal 
beliefs toward the adoption of “slow-kill” methods. The impact of differences in 
individual HW treatment decisions of each practitioner should be reduced in the analysis 
of overall HW treatment decision outcomes, as the mean of all practitioner estimates 
should comprise the outcome in the practice as a whole. The practitioner who made the 
lowest estimate for “slow-kill” practices in surgery a majority of the time, where 
heartworm management is less frequently encountered. Additionally, personal 
communications with this practitioner revealed that he places considerable importance on 
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the possibility of unsafe complications that may be caused by “slow-kill” treatment, and 
thus usually invests more resources into persuading clients to pursue adulticidal therapy. 
Although it is likely that this practitioner still underestimates his utilization of “slow-kill” 
despite his beliefs, this cannot be confirmed in this study. It would be beneficial for 
future analyses of clinical heartworm management decisions to address the impact of 
individual roles and beliefs on self-report by including practitioner-specific comparisons 
of estimates and actual behavior. However, this may prove difficult if patient cases are 
seen by multiple doctors, as treatment decisions may not be exclusive of other 
practitioners in the clinic.   
The results of this comparison, along with the generally low return rate on 
surveys, underscore concerns that practitioner questionnaires may be inaccurate tools for 
such data collection. However, one of the major limitations of this study is its small 
scope, as it enrolled only a single practice with four veterinarians and analyzed only three 
months’ activity, which is not a representative sample of veterinary practices. Thus, the 
results of this study cannot be generalized to other practices in the encompassing region. 
In reality, such extensive review of medical records is often impractical for the majority 
of veterinary practitioners. This is due to time constraints, digital medical recording 
practices which are not designed for retrieving such information, and paper medical 
records that are cumbersome and time-consuming to search through. Perhaps most 
significant is the fact that many medical records retain inadequate data to answer the 
questions of research. Thus, while small studies such as this one can provide a unique, 
deeper insight into HW disease management, self-report questionnaires, despite their 
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flaws, remain an important and efficient tool for investigating and understanding clinical 
behavior in veterinary practices.  
Another limitation of this study is the testing protocol used to determine 
heartworm-positive dogs in the study group, as it may have posed a limit on the numbers 
of HW-positive cases included in analysis. As previously stated, HW testing was done 
through the Idexx SNAP HW RT protocol, which utilizes ELISA to detect an antigen 
produced by the adult female heartworm. Although this test has a sensitivity of as much 
as 90% and is significantly more sensitive than other HW immunoassay products (Atkins, 
2003), false negatives are still possible for several reasons. Due to the long duration of 
the D. immitis life cycle from vector-transmitted larval stage to adult, this testing protocol 
can only detect HWI around six months after the onset of infection; in addition, worm 
burdens low in or absent of female worms will not produce detectable antigen, resulting 
in a false negative or misleading low antigen report (Atkins, 2005). For these reasons, the 
American Heartworm Society (AHS, 2014) advocates that practitioners include 
microfilarial testing, or direct observation of blood samples for existing microfilaria, in 
combination with antigen testing to detect HW in infected dogs with antigenemia. 
Recent studies have also demonstrated the role of antigen-antibody complexes in 
confounding antigen testing. In some studies, canine blood samples testing seronegative 
for HW antigen have been shown to test seropositive after the samples are heated; the 
researchers conducting these studies have proposed that heat treatment improves 
diagnostic accuracy of HWI since certain patients, such as those currently receiving ML 
preventive, may have immunologically inhibited D. immitis antigen during initial stages 
of infection (DiGangi et al., 2016; Savadelis et al., 2016; Valesquez et al., 2014). 
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However, the role of antigen-antibody complexes and their validity in representing active 
HWI is still disputed and requires continued research. 
As a result of these limitations, there may have been a greater number of positive 
dogs served in the practice than reported in this study. In order to overcome these 
limitations, future studies in this or other practices should employ microfilarial testing in 
addition to antigen testing protocols in order to decrease false negatives and provide a 
more accurate representation of HW prevalence. The AHS (2014) does not currently 
recommend heat treatment of patient serum for HW antigen testing because this would 
represent an off-label use of available antigen tests; regardless, it is possible that heat 
treatment could also increase sensitivity of HW diagnoses.  
 The ML preventive that was chosen for use in a majority of “slow-kill” treatments 
in this practice was injectable moxidectin. This may be due in part to the nature of this 
preventive and its decreased dependence on client compliance. Administration of 
injectable moxidectin is performed in the practice by a veterinary professional instead of 
by the client at home, and it requires less frequent administration (every six months) than 
other HWP products used in this practice (typically every month). When owners are 
responsible for administering monthly HWP, such as in the case of oral and topical 
products, there is rarely a reliable record of proper compliance (e.g. every 30 days). It is 
possible that pet owners may delay doses of medication or skip them entirely, permitting 
a window of infection in which the preventive is not 100% effective, and either overlook 
the lapse in coverage or choose not to report their mistakes. In contrast, administration of 
injectable moxidectin is reliably recorded through patient records and client purchase 
histories. Additionally, one veterinarian at this practice stated that since owners and their 
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pets must routinely return to the clinic for administration of injectable moxidectin, there 
are more opportunities to routinely examine the patients and a greater likelihood of 
regular HW testing. In support of this phenomenon, Zoetis, the manufacturer of the only 
currently available injectable moxidectin product, sponsored a study that found that 
veterinarians were able to address additional medical issues in 21.7% of patients who had 
presented to animal hospitals for administration of injectable moxidectin (Lavan & 
Login, 2015). Most importantly, injectable moxidectin seems to ensure the successful 
administration of HWP without lapses in coverage. 
 As previously stated, the AHS currently recommends against the off-label use of 
any ML preventives as an alternative adulticide therapy for HWI-positive patients. 
Despite this, studies have recently been performed to explore the efficacy of topical 
moxidectin/imidacloprid as an adulticide in combination with doxycycline. These 
ongoing studies have had promising results, indicating efficacy levels as high as 95.9% 
(Savadelis et al., 2016). Researchers presenting these studies have proposed topical 
moxidectin and oral doxycycline combination therapy as a safe alternative to 
melarsomine adulticidal therapy (Savadelis et al., 2016; Ames et al., 2016; Genchi & 
Kramer, 2016). While these studies explore the efficacy of topical moxidectin, the 
practice in this study primarily utilized injectable moxidectin, along with oral 
doxycycline in 85% of “slow-kill” cases. While moxidectin may have similar 
mechanisms of action despite different administration methods, further study would be 
necessary in confirming the efficacy of the drug in combination with the benefits of 
injection administration.  
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Factors Influencing Heartworm Disease Management 
The questionnaire results in this study reveal that clients who elect “slow-kill” 
therapy for their HW-positive dogs are primarily influenced by financial factors. As it has 
been previously stated that the validity of self-report should be scrutinized, this deserves 
further investigation beyond practitioner opinion. In fact, the importance of financial 
factors is supported by the state of the financial environment that pervades the MS delta 
region: that is, a significant percentage of clients in this region of high-density canine 
HW cases experience severe poverty. According to US Census data from 2010-2014, the 
county served by the practice in this study has a median annual household income 
($41,343) much lower than that of the United States ($53,482) and a poverty level 
(26.1%) higher than than of the United States (15.6%). Concurrently, many states 
included in the MS delta region have low household incomes and high poverty levels 
compared to the national average (US Census, 2015). As previously discussed, the cost of 
recommended HW treatment is higher than that of “slow-kill” treatment. According to an 
informal practitioner survey (AHS, 2013), the average cost of heartworm treatment for a 
40-lbs dog ranges from $1200-1800, which is 2.9-4.35% of the median household income 
in this region. Considering the importance of financial factors impacting HW 
management in the clinical environment and the results of academic inquiry, it may be 
beneficial to recognize the utility of “slow-kill” therapy in HW management, especially 
when it is impossible to mitigate the costs of melarsomine therapy. However, the lack of 
data concerning the actual costs of heartworm treatment methods is notable, and cost 
analyses would constitute an important step in understanding the financial aspects of 
heartworm treatment in order to develop more cost-efficient therapies. The results of this 
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study along with the relationship between economic trends and heartworm epidemiology 
suggest that these monetary factors play a significant role in HW management decisions 
and should not be overlooked. 
As previously stated, the costs of HWI extend beyond monetary considerations. 
HWI alone introduces irreversible pathology to the lungs and cardiovascular system of 
dogs, potentially limiting the pet’s lifespan (Atkins, 2005). The recommended HW 
treatment involves hospitalization, confinement, and restricted activity, resulting in the 
emotional stress of separation to both pet and pet owner. Some researchers have 
suggested that “slow-kill” combination therapy should be preferred over melarsomine 
therapy because they do not require exercise restriction (Savadelis et al., 2016; Ames et 
al., 2016), which is noteable regarding this study because practitioners cited the 
inconvenience of confinement as the second-most important factor influencing clients’ 
HW treatment decisions. Although cost analyses between HW treatment therapies are 
scarce, results from the American Heartworm Incidence Survey report that HW 
prevention costs are typically less than ten percent the cost of HW treatment (AHS, 
2011). Thus, maintaining good HW prevention protocols and increasing client 
compliance to existing HW preventives remains an essential and cost-effective method of 
decreasing HWI, along with protecting patients from HW pathology. 
 
Conclusions 
My study offers perspectives on the prevalence of “slow-kill” therapy for treatment of 
HWI and the discrepancies between medical records and practitioner opinions. The 
evidence from 40 HW-positive cases shows that the “slow-kill” method is a prevalent 
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HW treatment choice of clients and veterinarians despite AHS recommendations. 
Injectable moxidectin is the ML preventive of choice for “slow-kill” therapy in an 
overwhelming number of cases. Practitioner questionnaires reveal client financial 
concerns as the primary factor driving HW treatment towards “slow-kill” therapy and 
away from melarsomine therapy, although convenience also remains an important factor. 
As cost and convenience levels of current melarsomine adulticidal procedures may be 
impractical to change, there is a need for greater study on the efficacy and risks of the 
“slow-kill” method and the effects of different ML preventives and combination therapies 
for this off-label use. Such research for injectable moxidectin should be a particular 
priority in light of its prevalence in this study, the benefits of its administration method, 
and the recent studies regarding the efficacy of topical moxidectin. 
Comparison between these medical records and the estimates reported in the 
questionnaires also reveal discrepancies between practitioner opinion and the reality of 
HW management decisions in that “slow-kill” therapy is far more prevalent than 
estimated. While self-report questionnaires remain an important and useful research tool, 
additional research should be conducted to explore alternative methods of data collection 
for clinical management investigations to continue bridging the gap between academic 
and clinical environments of HW disease management. For example, it would be 
beneficial to implement a clinical survey to determine the success rate of “slow-kill” 
therapy in reverting HW-positive antigen tests within practices that have already elected 
to use “slow-kill”. Ideally, participating practices would have a large sample size of HW 
positive canines undergoing this form of treatment. Such a study could provide 
information on clinical success rates for different HW preventives, estimates for average 
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length of administration required for remission, and documentation of possible risks and 
side effects, greatly adding to the current understanding of “slow-kill” efficacy and risks. 
Additionally, while case studies such as this one are a useful tool, development of 
software allowing more efficient yet accurate data collection from multiple practices 
would serve extremely useful as well. 
Ultimately the data, in addition to WOI analyses, suggest that poor client compliance 
with HW preventive administration remains the predominant cause of HW infection. This 
suggests that practicing veterinarians should take efforts to ensure client compliance with 
existing, effective HW preventatives in order to reduce HW disease prevalence, 
regardless of local parasite resistance. While heartworm resistance to MLs is certainly 
deserving of continued study, lack of compliance to existing HWP protocols must first be 
addressed in order to provide a more accurate understanding of the impact of resistance. 
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